Loading provider…
Loading provider…
Medical Oncology Physician in Chicago, IL
NPI: 1134448665Primary Practice Location
THE UNIVERSITY OF CHICAGO MEDICAL CENTER
5700 S Maryland Ave, Chicago, IL
Primary Employer
The University of Chicago Medical Center
uchicagomedicine.org
HQ Phone
Get Alexander's Phone Numberphone_androidMobile
Get Alexander's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardIL State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 42 | 85 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 27 | 39 |
| 3 | 99213Established patient office or other outpatient visit, typically 15 minutes | 23 | 31 |
| 4 | 99205New patient office or other outpatient visit, typically 60 minutes | 21 | 21 |
| 5 | 99223Initial hospital inpatient care, typically 70 minutes per day | 15 | 16 |
Authors: Olasubomi Omoleye, Kirti Kulkarni, Frederick Howard
Journal: Radiol Artif Intell
Publication Date: 2023-07-26
Validation of the RSClin risk calculator in the National Cancer Data Base.
Authors: Frederick Howard, Olwen Hahn, Sarah Shubeck, Rita Nanda, Gini Fleming, Nora Jaskowiak
Journal: Cancer
Publication Date: 2023-12-26
Machine Learning-Guided Adjuvant Treatment of Head and Neck Cancer.
Lead Sponsor: Hookipa Biotech GmbH
Intervention / Treatment: DRUG: HB-201 intravenous administration., DRUG: HB-202 intravenous administration alternating with HB-201 intravenous administration., DRUG: HB-201 intravenous administration + standard of care regimen including pembrolizumab., DRUG: HB-202 / HB-201 alternating intravenous administration + pembrolizumab., DRUG: HB-202 / HB-201 alternating intravenous administration + standard of care regimen including pembrolizumab., DRUG: HB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C)
Lead Sponsor: University of Chicago
Intervention / Treatment: DRUG: Docetaxel, DRUG: Pembrolizumab
Lead Sponsor: Genocea Biosciences, Inc.
Intervention / Treatment: DRUG: Cyclophosphamide, DRUG: Fludarabine, DRUG: IL-2, BIOLOGICAL: GEN-011